Optimization of Thymidine Kinase-Based Safety Switch for Neural Cell Therapy

Cell therapies based on pluripotent stem cells (PSC), have opened new therapeutic strategies for neurodegenerative diseases. However, insufficiently differentiated PSC can lead to tumor formation. Ideally, safety switch therapies should selectively kill proliferative transplant cells while preserving post-mitotic neurons. In this study, we evaluated the potential of nucleoside analogs and thymidine kinase-based suicide genes. Among tested thymidine kinase variants, the humanized SR39 (SR39h) variant rendered cells most sensitive to suicide induction. Unexpectedly, post-mitotic neurons with ubiquitous SR39h expression were killed by ganciclovir, but were spared when SR39h was expressed under the control of the cell cycle-dependent Ki67 promoter. The efficacy of six different nucleoside analogs to induce cell death was then evaluated. Penciclovir (PCV) showed the most interesting properties with an efficiency comparable to ganciclovir (GCV), but low toxicity. We tested three nucleoside analogs in vivo: at concentrations of 40 mg/kg/day, PCV and GCV prevented tumor formation, while acyclovir (ACV) did not. In summary, SR39h under the control of a cell cycle-dependent promoter appears most efficient and selective as safety switch for neural transplants. In this setting, PCV and GCV are efficient inducers of cell death. Because of its low toxicity, PCV might become a preferred alternative to GCV.

[1]  H. Okano,et al.  Increased Cytotoxicity of Herpes Simplex Virus Thymidine Kinase Expression in Human Induced Pluripotent Stem Cells , 2019, International journal of molecular sciences.

[2]  S. James,et al.  Antiviral Therapies for Herpesviruses: Current Agents and New Directions. , 2018, Clinical therapeutics.

[3]  Zoltan Simandi The Role of DNA Polymerase β in Neural Genome Stability , 2017, The Journal of Neuroscience.

[4]  K. Krause,et al.  Elimination of proliferating cells from CNS grafts using a Ki67 promoter-driven thymidine kinase , 2016, Molecular therapy. Methods & clinical development.

[5]  G. Andrei,et al.  Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymerase , 2016, Nucleic acids research.

[6]  E. Salido,et al.  PrimPol, an Archaic Primase/Polymerase Operating in Human Cells , 2013, Molecular cell.

[7]  J. Campisi,et al.  Mitochondrial DNA damage induces apoptosis in senescent cells , 2013, Cell Death and Disease.

[8]  G. Evans,et al.  Suicide Gene Therapy by Herpes Simplex Virus-1 Thymidine Kinase (HSV-TK) , 2011 .

[9]  A. Składanowski,et al.  H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy , 2010, Journal of nucleic acids.

[10]  H. Colom,et al.  Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[11]  M. Black,et al.  Fusion Enzymes Containing HSV-1 Thymidine Kinase Mutants and Guanylate Kinase Enhance Prodrug Sensitivity In Vitro and In Vivo , 2009, Cancer Gene Therapy.

[12]  C. Wiegand,et al.  Methods for the measurement of cell and tissue compatibility including tissue regeneration processes , 2008, GMS Krankenhaushygiene interdisziplinar.

[13]  F. Edwards,et al.  Differential development of neuronal physiological responsiveness in two human neural stem cell lines , 2007, BMC Neuroscience.

[14]  A. Trounson,et al.  Human embryonic stem cells: prospects for development , 2004, Development.

[15]  P. Wutzler,et al.  Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. , 2003, Antiviral research.

[16]  M. Black,et al.  Characterization of Herpes Simplex Virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity , 2002, Protein science : a publication of the Protein Society.

[17]  D. Michel,et al.  GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E. , 2002, Antiviral research.

[18]  P. Watts,et al.  Ganciclovir and Penciclovir, but Not Acyclovir, Induce Apoptosis in Herpes Simplex Virus Thymidine Kinasetransformed Baby Hamster Kidney Cells , 2001, Antiviral chemistry & chemotherapy.

[19]  G. Dachs,et al.  Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives , 2001, Journal of cellular physiology.

[20]  M. Tomicic,et al.  Cytogenetic genotoxicity of anti-herpes purine nucleoside analogues in CHO cells expressing the thymidine kinase gene of herpes simplex virus type 1: comparison of ganciclovir, penciclovir and aciclovir. , 2000, Mutagenesis.

[21]  M. Nassiri,et al.  Nonnucleoside Pyrrolopyrimidines with a Unique Mechanism of Action against Human Cytomegalovirus , 1999, Antimicrobial Agents and Chemotherapy.

[22]  H. Lazarus,et al.  Intravenous Penciclovir for Treatment of Herpes Simplex Infections in Immunocompromised Patients: Results of a Multicenter, Acyclovir-Controlled Trial , 1999, Antimicrobial Agents and Chemotherapy.

[23]  S. Kain,et al.  Generation of Destabilized Green Fluorescent Protein as a Transcription Reporter* , 1998, The Journal of Biological Chemistry.

[24]  C. Cox,et al.  Fusion of green fluorescent protein with the Zeocin-resistance marker allows visual screening and drug selection of transfected eukaryotic cells. , 1998, BioTechniques.

[25]  Gerd Folkers,et al.  The structures of thymidine kinase from Herpes simplex virus type 1 in complex with substrates and a substrate analogue , 1997, Protein science : a publication of the Protein Society.

[26]  B. Schweitzer,et al.  Solution structure of a DNA decamer containing the antiviral drug ganciclovir: combined use of NMR, restrained molecular dynamics, and full relaxation matrix refinement. , 1997, Biochemistry.

[27]  S. Clarke,et al.  Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[28]  J. Reardon Herpes simplex virus type 1 and human DNA polymerase interactions with 2'-deoxyguanosine 5'-triphosphate analogues. Kinetics of incorporation into DNA and induction of inhibition. , 1989, The Journal of biological chemistry.

[29]  R. Miller,et al.  Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. , 1980, The Journal of biological chemistry.

[30]  M. Nowakowska,et al.  Acyclovir in the Treatment of Herpes Viruses - a Review. , 2018, Current medicinal chemistry.

[31]  A. Björklund,et al.  Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. , 2014, JAMA neurology.

[32]  K. Krause,et al.  Engineering of midbrain organoids containing long-lived dopaminergic neurons. , 2014, Stem cells and development.

[33]  E. De Clercq Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. , 2004, Biochemical pharmacology.

[34]  M. Black,et al.  Herpes Simplex Virus-1 Thymidine Kinase Mutants Created by Semi-Random Sequence Mutagenesis Improve Prodrug-mediated Tumor Cell Killing 1 , 2001 .

[35]  M. Tomicic,et al.  Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: Implications for gene therapeutic approaches , 2000, Cancer Gene Therapy.

[36]  B. Dörken,et al.  Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. , 1997, Cancer gene therapy.